These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Prevalence and molecular characterization of clinical isolates of Escherichia coli expressing an AmpC phenotype. Jørgensen RL, Nielsen JB, Friis-Møller A, Fjeldsøe-Nielsen H, Schønning K. J Antimicrob Chemother; 2010 Mar; 65(3):460-4. PubMed ID: 20097787 [Abstract] [Full Text] [Related]
4. Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered in a French hospital. Mammeri H, Eb F, Berkani A, Nordmann P. J Antimicrob Chemother; 2008 Mar; 61(3):498-503. PubMed ID: 18250231 [Abstract] [Full Text] [Related]
5. Molecular characterization of the gene encoding a new AmpC beta-lactamase in Acinetobacter baylyi. Beceiro A, Pérez-Llarena FJ, Pérez A, Tomás Mdel M, Fernández A, Mallo S, Villanueva R, Bou G. J Antimicrob Chemother; 2007 May; 59(5):996-1000. PubMed ID: 17403709 [Abstract] [Full Text] [Related]
11. Increase in ampC promoter strength due to mutations and deletion of the attenuator in a clinical isolate of cefoxitin-resistant Escherichia coli as determined by RT-PCR. Tracz DM, Boyd DA, Bryden L, Hizon R, Giercke S, Van Caeseele P, Mulvey MR. J Antimicrob Chemother; 2005 May; 55(5):768-72. PubMed ID: 15761065 [Abstract] [Full Text] [Related]
12. Emergence of CTX-M-12 extended-spectrum beta-lactamase-producing Escherichia coli in Korea. Bae IK, Lee YN, Hwang HY, Jeong SH, Lee SJ, Kwak HS, Song W, Kim HJ, Youn H. J Antimicrob Chemother; 2006 Dec; 58(6):1257-9. PubMed ID: 17003059 [Abstract] [Full Text] [Related]
13. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Oteo J, Delgado-Iribarren A, Vega D, Bautista V, Rodríguez MC, Velasco M, Saavedra JM, Pérez-Vázquez M, García-Cobos S, Martínez-Martínez L, Campos J. Int J Antimicrob Agents; 2008 Dec; 32(6):534-7. PubMed ID: 18775649 [Abstract] [Full Text] [Related]
14. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition. Bethel CR, Hujer AM, Helfand MS, Bonomo RA. FEMS Microbiol Lett; 2004 May 01; 234(1):99-103. PubMed ID: 15109726 [Abstract] [Full Text] [Related]
15. Comment on: extension of the hydrolysis spectrum of AmpC beta-lactamase of Escherichia coli due to amino acid insertion in the H-10 helix. Sohn SG, Lee JJ, Sohn ES, Kang LW, Lee SH. J Antimicrob Chemother; 2008 Apr 01; 61(4):965-6; author reply 966. PubMed ID: 18227084 [No Abstract] [Full Text] [Related]